Top Tweets for #ctrcd
Sacubitril/Valsartan in #Anthracycline-Treated Patients: SR-MA
Current evidence is insufficient to
determine whether Sac/Val reduces #CTRCD risk because of heterogeneous definitions used in the studies
https://t.co/6XxPkYRTIr
#JACCCardioOnco #JACC @JACCJournals
@JHeartFailureS
第12回日本心筋症研究会 @京都
https://t.co/ht67G0P0UQ
💛シンポジウム
#がん関連治療関連心筋障害
循環器内科医はどう捉えるべきか
"from bench to bedside" の布陣で凄そうです
✅「#CTRCD の臨床管理：#GDMT の最適化と新規治療の展望」 志賀太郎 がん有明病院
#腫瘍循環器
🎧 How should we monitor the heart during HER2+ breast cancer therapy?
In this ESC CardioOncology #CardioTalk, Dr @Massimi78530343 & Dr @JLiu_MSKCardOnc discuss about HER2 cardiotoxicity, risk stratification, & monitoring to prevent #CTRCD
🎧: https://t.co/fFm35VsKQW
First data of #CardioOncology #CTRCD outcomes from the 1st prospective registry #ICOP in the #ArabianMiddleEast region just published #GlobalHeart @worldheartfed
https://t.co/gBq1puTAGs.
@TeresaLpezFdez1 @ICOSociety
#CTRCD may be identifiable before therapy begins. In #HER2+ #breastCA pretreatment endothelial & inflammatory biomarkers: ANGPT2, MPO, & endoglin, outperformed clinical & CMR in predicting cardiac dysfunction https://t.co/ZTkWXSjiRQ
#JACCCardioOnc #BCsm @dineshpmcc1 @FishLab_UHN
Exciting work by @FishLab_UHN using #cardioncology cohorts @PMunkCardiacCtr / combined blood biomarkers approach to predict #CTRCD @JACCJournals even before cancer therapy. Reach out if u have banked blood for additional external validation.@ICOSociety @CCardiacON @UHN @UofT
Excited to share our paper https://t.co/qDpeJLoyUg. Together with @dineshpmcc1 and led by Dakota Gustafson and Priya Mistry, we show that elevated levels of inflammatory and endothelial activation biomarkers before treatment can predict cancer therapy-related cardiac dysfunction.
#アントラサイクリン #CTRCD
#腫瘍循環器
✅NTproBNPガイドの心保護治療
✅設定上限を超えたら心保護介入
▶️現実的で安全に実施可能
将来的には
“全員予防” ではなく “高リスク者のみ心保護” という
より個別化された安全な治療戦略の実現に道を開く可能性があります💙
📰Read the latest from the Thalheimer Center! https://t.co/mLQxzm1MpN
🫀This study found that in pts w/ #BreastCancer or #Lymphoma treated w/ anthracyclines, NT-proBNP–guided cardioprotection is safe, feasible, and might result in some early improvements in heart function!
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes
SGLT2i administration was associated with a significantly decreased risk of developing CTRCD in patients with T2DM and cancer
@JACCJournals @ACCinTouch @escardio @ESC_Journals @DrMarthaGulati @SubodhVermaMD @hvanspall @hvanspall @Hragy @AnastasiaSMihai
https://t.co/3ZlzBsnFOa
Inspiring and feasible model #OptimismModel by @IsraaFadhilYas1 #CardiologyClinicalPharmacist to break bad news and improve adherence and outcomes in patients with #CTRCD @worldheartfed #GlobalHeart @WomenAs1 @mirvatalasnag @RashaKaddoura2 @aayshacader @RaulSantos @mmamas1973
In a world full of broken hearts and spirits, “Optimism Model” could be a cure for some of those hearts… Optimism Model by a Cardiology Pharmacist in Breaking Bad News Among Patients with #CTRCD published #GlobalHeart @worldheartfed
https://t.co/ZAHMglixuD
@TeresaLpezFdez1
In a world full of broken hearts and spirits, “Optimism Model” could be a cure for some of those hearts… Optimism Model by a Cardiology Pharmacist in Breaking Bad News Among Patients with #CTRCD published #GlobalHeart @worldheartfed
https://t.co/ZAHMglixuD
@TeresaLpezFdez1
Reduced echo monitoring every 6 months is safe and feasible for low risk HER2+ BC patients, per #Anthony Yu et al. A key step toward evidence-based, risk-adapted monitoring. #CardioOnc #CTRCD @JACCJournals @ksase @dineshpmcc1 @ICOSociety
What’s the future needs for #CardioOncology trials?
Perfectly summarized by @PennThalheimer at #ESCardioOnco2025🫀
📍Define mechanisms linking cancer & #CTRCD
📍Expand the field of #ReverseCardioOncology
📍Stratify individual patient risk
📍Enable precise phenotyping
📍more #AI innovation
📍Advance cardioprotective strategies
📍Rethink clinical trial design
📍Ensure equitable, inclusive, high-quality care globally
📍Continue building guidance to move the field forward
@escardio
@TeresaLpezFdez1 @drmirabel @DrJESalem @DrRaulCordoba @LlamedoClara @Massimi78530343 @Dr_Mike_Fradley @sdent_cardioonc @VDelgadoGarcia @JACCJournals
Preclinical models in #CardioOncology by Dr #AlessandraGhigo 🧬🫀
📍 Intercellular cross-talk remains poorly defined in preclinical #cardiooncology models
📍 Single-cell & single-nucleus RNA sequencing offer powerful potential to unravel the communication networks driving #CTRCD
#ESCardioOnco2025 @escardio
@LlamedoClara @VDelgadoGarcia @DrRaulCordoba @Massimi78530343 @Dr_Mike_Fradley @Borjaibanez1 @PeterMoliner @TeresaLpezFdez1
Are we missing something in #CardioOncology research?🧬🫀
Prof #RudolfDeBoer shares key insights on pre-clinical models for #CTRCD at #HeartFailure2025:
📍Current pre-clinical research doesn’t align with onco RCTs
📍Only 6% of onco RCTs take CTRCD into account
📍Needs for multiple complementary models to catch the complex, interrelated pathways
#ESCardioOnco
@Massimi78530343 @TeresaLpezFdez1 @FarmakisD @drmirabel @MariaSolAndres1 @LlamedoClara @KathOzaeta @drtarsh
How do you manage your patients with improved #CTRCD after cardioprotective therapy?
Join experts for the next IC-OS Journal Club and explore the long-term outcomes of discontinuing therapy in CTRCD patients 🔗 https://t.co/hxQ3mn2PQB
🗓️ On 1 May at 14:00 BST | 09:00 EDT, Dr Hyukjin Park, Dr Jose Alvarez-Cardona, Dr Dan Lenihan and Dr Joe Carver will discuss:
• Latest research on the safe withdrawal of therapy
• Expert recommendations for managing improved CTRCD
• Practical insights for real-world application
Don't miss out! Sign up now and stay ahead in cardio-oncology care.
#CardioOnc #Cardiology #CardioX #CardioTwitter @ICOSociety
Dr. Anthony Yu of @MSKCancerCenter presenting a strong case for #echofirst for #CTRCD surveillance and decreased frequency of surveillance for well defined LOW RISK breast cancer patients. #CardioOnc #GCOS2024
Thrilled to share our work in #JACC: CardioOnc & be presenting at #GCOS2024! #SGLT2i associated with ⬇️ risk of #CTRCD in patients with cancer and T2DM. A hopeful advance for survivorship & CardioOncology! Thankful to mentors @SarjuGanatraMD @SaurabhSDani https://t.co/bXPnpmNvt6
International Cardio-Oncology Society(IC-OS)のオフィシャルジャーナルであるCardio-Oncologyに論文掲載！
トラスツズマブを投与された唾液腺癌患者でCTRCDの頻度の性差に有意差なし！男性でのHER2阻害薬CTRCDを検証した研究は貴重です✨
#cardiooncology #CTRCD #HER2
https://t.co/CKGlQnKfiy
🌟Excited to see that our work on variability of #LVEF measurement by different vendors can impact #CTRCD was in the 1st issue of the new Journal of Nuclear Cardiology👇
@GiselleSA_MDPhD @DrSFeldman @AnoshiaMD @RutgersCVI @Rutgers_card #cvnuc @MyASNC #CardioOnc
Learn about variability in LVEF assessments and its impact on cardiotoxicity detection.
Suero-Abreu et al (https://t.co/9zwSdPbLDg)
Editorial (https://t.co/f1zwr5mv3e)
#CTRCD #LVEF #ERNA @alfonsowallermd @GiselleSA_MDPhD #cardioonc @MyASNC #cvnuc
Last Seen Hashtags on Sotwe
donwilliamsgroup
Seen from United States
snapchat(*)+filter:videos()
Seen from New Zealand
petite
Seen from United States
anxiouspanda
Seen from United Kingdom
MightyJoeYoung
Seen from United States
跟扫
Seen from United States
minichat
Seen from Italy
SustainableFashionForum
Seen from United States
Automodsau
Seen from United States
Snowcunny
Seen from Australia
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers